Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal cognitive assessment using the Cumulus NeuLogiq platform in amyotrophic lateral sclerosis and frontotemporal dementia.

Scientific reports·2026
Same author

Deep learning for the joint analysis of item-level longitudinal and survival data.

Journal of applied statistics·2026
Same author

Exploring physiotherapists' role in work-focused health care and fit note use: Barriers, facilitators, and recommendations.

Physiotherapy·2026
Same author

Multi-institutional MRI-based radiomic pilot study to measure the variations between scanner vendors and imaging sessions.

Frontiers in oncology·2026
Same author

The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.

Nature medicine·2026
Same author

AI Ethics Guidelines: Time to Include Animals.

Science and engineering ethics·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Cardiovascular-kidney-metabolic syndrome stage modifies the efficacy of intensive blood pressure control on cognitive outcomes: A post hoc analysis of SPRINT MIND.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evidence of APOE4-related brain vulnerabilities in verbal memory systems in midlife women.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Changes in DNA methylation-based aging predicts brain damage and dementia and reflects life-course cardiovascular risk.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Elimination of tau tangles and soluble aggregates with the small molecule ACI-16664 prevents neurodegeneration in vivo.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Altered brain glucose metabolism and connectivity in young adults with obstructive sleep apnea.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Rianne N Esquivel1, Shriya Mathur1, Christine Parker2

  • 1GSK, Collegeville, PA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

Blood biomarkers like PrecivityAD and pTau181 can accelerate Alzheimer's disease clinical trials by prescreening for amyloid positivity. This reduces patient burden and operational costs associated with traditional confirmatory testing.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Biomarkers
  • Clinical Trials

Background:

  • Clinical trials for early Alzheimer's disease (AD) face slow enrollment due to low amyloid positivity rates.
  • Confirmatory testing (CSF biomarkers, amyloid PET) increases patient burden and operational challenges.
  • Blood-based biomarkers offer a potential solution for prescreening and enriching trial populations.

Purpose of the Study:

  • To evaluate the efficacy of blood-based biomarkers (PrecivityAD and Elecsys pTau181) in prescreening for amyloid positivity in early AD clinical trials.
  • To assess the impact of these biomarkers on reducing the need for invasive confirmatory testing.

Main Methods:

  • Incorporated PrecivityAD and Elecsys pTau181 assays into the screening process for the PROGRESS-AD phase 2 trial.
  • Compared blood biomarker results with amyloid PET and CSF (Aβ42/40 ratio) for ROC analysis.
  • Analyzed positive percent agreement (PPA), negative percent agreement (NPA), and positive predictive value (PPV) against confirmatory tests.

Main Results:

  • pTau181 showed PPA of 85.0% and NPA of 59.5%.
  • PrecivityAD demonstrated PPA of 64.6% and NPA of 42.9%.
  • PrecivityAD had a PPV of 96.4%, and pTau181 had a PPV of 90.0%, significantly reducing screen failure rates to 9.9%.

Conclusions:

  • Blood-based biomarkers significantly reduce the need for CSF or PET testing in early AD trials.
  • These biomarkers can decrease participant burden, improve trial accessibility, and enhance clinical trial design.
  • Further research is needed to address limitations such as incomplete confirmatory results for amyloid-negative individuals and potential biases.